OpenAI 收购 Orchestra Bio，AI 智能体切入药物研发全流程
OpenAI 收购了做药物研发智能体的 Orchestra Bio，AI 不只写代码写文章，还能盯着临床试验排期了，做医药或投资方向的朋友可以看看。
OpenAI 收购 Orchestra Bio，获得能协调药物开发流程的智能体，可以追踪诸如生产批次失败导致临床试验延后这类具体问题。该收购与 Rosalind 产品配合，目标是把 AI 嵌入科学研究以及药物交付给患者的运营环节。药物研发与疾病治疗因此被视为 AI 落地的主要方向之一，Anthropic 同日也发布了类似动向。
Many people are asking how to invest in AI and data centers. Here's a very good example of where AI is headed:
OpenAI’s acquisition of Orchestra Bio adds agents that coordinate drug development, tracking how problems like a failed manufacturing batch could delay clinical trials. Paired with Rosalind, it shows toward a broader ambition: embedding AI across both scientific research and the operational work needed to bring medicines to patients.
Drug research and disease cure are among the significant fields in which AI extends and will make tremendous progress. Anthropic published something similar today.
